Protein kinases in hormonal regulation of adipocyte metabolism.
Författare
Summary, in English
Abstract
Along with liver and muscle tissue, adipose tissue helps maintain normal levels of
glucose and lipids in the blood and has a very important role when it comes to storing
lipids that can provide whole-body energy. After a meal is ingested, adipocytes take
up glucose from the circulation and use it as a substrate for synthesis of new fatty
acids (FAs) in a process known as de novo fatty acid synthesis, as well as for synthesis
of glycerol. Adipocytes also take up fatty acids from the circulation and incorporate
both newly synthesized and imported FAs into triacylglycerides (TAGs), in a process
known as lipogenesis. TAGs are stored in large lipid droplets in the cytosol, and
during fasting, or in response to physical exercise, they are hydrolysed in a process
known as lipolysis, in which FAs are released into the bloodstream for use as energy
substrates in other tissues. These cycles of lipogenesis and lipolysis are controlled by
the concerted actions of insulin, a hormone that is secreted by the pancreas and
catecholamines, hormones that are secreted by the adrenal glands, or derive from the
nervous system. Both glucose- and fatty acid uptake, as well as lipid storage and
mobilization, are regulated by cellular signaling, and kinases are central enzymatic
players in hormone-induced cellular signaling. A dysfunctional adipose tissue can
contribute to insulin resistance in many obese individuals. Therefore it is important
to elucidate the cellular mechanisms that govern metabolic processes in adipocytes.
Insulin is the hormone that promotes glucose uptake and lipogenesis in adipocytes,
and when it induces glucose uptake, insulin exerts it actions through protein kinase B
(PKB). Although PKB is known to mediate many effects of insulin, its role in
lipogenesis in adipocytes is less clear. We show that PKB is important for the effects
of insulin on lipogenesis (de novo and total). We also reveal that PKB can regulate
Amp-activated protein kinase (AMPK) in adipocytes by a mechanism previously only
seen in heart muscle cells. AMPK is a sensor of cellular energy status and known to
inhibit lipogenesis. We speculate that insulin possibly mediates its lipogenic effects via
a decrease in AMPK activity accomplished by PKB-phosphorylation of S485 on
AMPK.
Furthermore, we find that salt-inducible kinase 3 (SIK3), a kinase that belongs to the
AMPK-related family of kinases, and displays structural similarities to AMPK, can be
regulated by catecholamines in adipocytes. Catecholamines are hormones that bind to
β-adrenergic receptors and act by increasing cellular levels of cAMP, which in turn
activates protein kinase A (PKA). We find that in response to such β-adrenergic
stimuli, SIK3 is phosphorylated on multiple serine and threonine residues. This 10
regulation coincides with an increase in binding of SIK3 to 14-3-3 molecules. 14-3-3
proteins are cellular scaffolding proteins that can result in cellular re-localization of
their binding partners or in their binding to other proteins or lipids. We find that
when SIK3 is phosphorylated in response to β-adrenergic stimuli, the kinase does not
re-localize, but is partially de-activated. We speculate that SIK3 could potentially have
a role in adipocyte metabolism, as it is regulated by catecholamines in this tissue.
Finally, we address the current understanding of the role for AMPK in modulation of
the effects of insulin and catecholamines on glucose uptake and lipid metabolism. To
this date, it has been suggested that AMPK reduces insulin-induced glucose uptake
and lipogenesis, as well as inhibits catecholamine-induced lipolysis in adipocytes.
These findings are mainly based on studies performed with AMPK activating agents
that act on AMPK in an indirect manner. We have used the allosteric activator
A769662, that binds directly to AMPK, and find that AMPK does not appear to
modulate hormonally induced glucose uptake, lipolysis or total lipogenesis. However,
when we specifically measured the synthesis of new FAs, using acetate as a lipogenic
substrate (as opposed to using glucose as a substrate, a molecule which can participate
in both FA and glycerol synthesis), we observe that AMPK does indeed reduce
insulin-induced de novo fatty acid synthesis.
Collectively, we add novel findings to the available knowledge on key kinases and
cellular signaling in adipocyte metabolism. Our findings contribute to the
understanding of insulin- and catecholamine-mediated control of lipid storage in
adipose tissue, a biological function that, when dysfunctional, is strongly linked to
insulin resistance and type 2 diabetes (T2D).
Along with liver and muscle tissue, adipose tissue helps maintain normal levels of
glucose and lipids in the blood and has a very important role when it comes to storing
lipids that can provide whole-body energy. After a meal is ingested, adipocytes take
up glucose from the circulation and use it as a substrate for synthesis of new fatty
acids (FAs) in a process known as de novo fatty acid synthesis, as well as for synthesis
of glycerol. Adipocytes also take up fatty acids from the circulation and incorporate
both newly synthesized and imported FAs into triacylglycerides (TAGs), in a process
known as lipogenesis. TAGs are stored in large lipid droplets in the cytosol, and
during fasting, or in response to physical exercise, they are hydrolysed in a process
known as lipolysis, in which FAs are released into the bloodstream for use as energy
substrates in other tissues. These cycles of lipogenesis and lipolysis are controlled by
the concerted actions of insulin, a hormone that is secreted by the pancreas and
catecholamines, hormones that are secreted by the adrenal glands, or derive from the
nervous system. Both glucose- and fatty acid uptake, as well as lipid storage and
mobilization, are regulated by cellular signaling, and kinases are central enzymatic
players in hormone-induced cellular signaling. A dysfunctional adipose tissue can
contribute to insulin resistance in many obese individuals. Therefore it is important
to elucidate the cellular mechanisms that govern metabolic processes in adipocytes.
Insulin is the hormone that promotes glucose uptake and lipogenesis in adipocytes,
and when it induces glucose uptake, insulin exerts it actions through protein kinase B
(PKB). Although PKB is known to mediate many effects of insulin, its role in
lipogenesis in adipocytes is less clear. We show that PKB is important for the effects
of insulin on lipogenesis (de novo and total). We also reveal that PKB can regulate
Amp-activated protein kinase (AMPK) in adipocytes by a mechanism previously only
seen in heart muscle cells. AMPK is a sensor of cellular energy status and known to
inhibit lipogenesis. We speculate that insulin possibly mediates its lipogenic effects via
a decrease in AMPK activity accomplished by PKB-phosphorylation of S485 on
AMPK.
Furthermore, we find that salt-inducible kinase 3 (SIK3), a kinase that belongs to the
AMPK-related family of kinases, and displays structural similarities to AMPK, can be
regulated by catecholamines in adipocytes. Catecholamines are hormones that bind to
β-adrenergic receptors and act by increasing cellular levels of cAMP, which in turn
activates protein kinase A (PKA). We find that in response to such β-adrenergic
stimuli, SIK3 is phosphorylated on multiple serine and threonine residues. This 10
regulation coincides with an increase in binding of SIK3 to 14-3-3 molecules. 14-3-3
proteins are cellular scaffolding proteins that can result in cellular re-localization of
their binding partners or in their binding to other proteins or lipids. We find that
when SIK3 is phosphorylated in response to β-adrenergic stimuli, the kinase does not
re-localize, but is partially de-activated. We speculate that SIK3 could potentially have
a role in adipocyte metabolism, as it is regulated by catecholamines in this tissue.
Finally, we address the current understanding of the role for AMPK in modulation of
the effects of insulin and catecholamines on glucose uptake and lipid metabolism. To
this date, it has been suggested that AMPK reduces insulin-induced glucose uptake
and lipogenesis, as well as inhibits catecholamine-induced lipolysis in adipocytes.
These findings are mainly based on studies performed with AMPK activating agents
that act on AMPK in an indirect manner. We have used the allosteric activator
A769662, that binds directly to AMPK, and find that AMPK does not appear to
modulate hormonally induced glucose uptake, lipolysis or total lipogenesis. However,
when we specifically measured the synthesis of new FAs, using acetate as a lipogenic
substrate (as opposed to using glucose as a substrate, a molecule which can participate
in both FA and glycerol synthesis), we observe that AMPK does indeed reduce
insulin-induced de novo fatty acid synthesis.
Collectively, we add novel findings to the available knowledge on key kinases and
cellular signaling in adipocyte metabolism. Our findings contribute to the
understanding of insulin- and catecholamine-mediated control of lipid storage in
adipose tissue, a biological function that, when dysfunctional, is strongly linked to
insulin resistance and type 2 diabetes (T2D).
Publiceringsår
2014
Språk
Engelska
Publikation/Tidskrift/Serie
Lund University Faculty of Medicine Doctoral Dissertation Series
Volym
2014:90
Fulltext
Dokumenttyp
Doktorsavhandling
Förlag
Protein Phosphorylation, Faculty of Medicine
Ämne
- Endocrinology and Diabetes
Nyckelord
- Adipocyte
- PKB
- AMPK
- SIK3
- insulin
- catecholamines
- lipolysis
- lipogenesis
- glucose uptake
- de novo fatty acid synthesis
- A769662
- Akti
- cAMP
Status
Published
Forskningsgrupp
- Protein Phosphorylation
Handledare
ISBN/ISSN/Övrigt
- ISSN: 1652-8220
- ISBN: 978-91-7619-019-7
Försvarsdatum
5 september 2014
Försvarstid
09:00
Försvarsplats
Segerfalksalen, BMC A10, Sölvegatan 17, Lund.
Opponent
- Jørgen Wojtaszewski (Professor)